The Cigna

Cigna's PBM Business Unscathed by Recent Regulatory Developments

信诺保险

Cigna: RBC Capital Maintains Outperform Rating, PT Down to $333.

Cigna's 15min chart shows RSI overbought and KDJ death cross.

Cigna: Barclays Maintains Overweight Rating, PT Cut to $303 from $305

Cigna Guggenheim Upgrades to Buy, Raises PT to $334 from $318

Catalyst<ul> <li>Most analysts rate CI Buy or Strong Buy, showing broad institutional optimism.</li></ul>Risk<ul> <li>Technical indicators show that the market is in a volatile state, and the direction is not clear enough.</li> <li>Fund flow analysis indicates an overall negative trend with net outflows across most investor size categories.</li></ul>

Key Factors

Cigna's Express Scripts settled an FTC lawsuit over insulin price manipulation without admitting wrongdoing or paying a fine, under a 10-year agreement to change business practices.Cigna raised its quarterly dividend by 3.3% to $1.56 per share, with a forward yield of 2.3%, payable on March 19.Cigna reported Q4 revenue of $274.9 billion, up 11% year-over-year, and adjusted earnings per share of $29.84 for 2025, with 2026 guidance set at a minimum of $30.25 per share.

CI News